<DOC>
	<DOCNO>NCT02829268</DOCNO>
	<brief_summary>Wolfram syndrome rare genetic disorder characterize juvenile-onset diabetes mellitus , diabetes insipidus , optic nerve atrophy , hear loss , neurodegeneration . The purpose study assess safety tolerability dantrolene sodium patient Wolfram syndrome . In addition , assess efficacy dantrolene sodium cardinal manifestation Wolfram syndrome , include visual acuity , remain beta cell function , neurological function . There screen period 56 day , 24-week treatment period , 4-week safety follow-up period . Study assessment include medical &amp; medication history , physical exam , neurological exam , eye exam , endocrine exam , vital sign , height , weight , electrocardiogram , blood urine test , pregnancy test applicable , questionnaire .</brief_summary>
	<brief_title>A Clinical Trial Dantrolene Sodium Pediatric Adult Patients With Wolfram Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Wolfram Syndrome</mesh_term>
	<mesh_term>Optic Atrophy</mesh_term>
	<mesh_term>Dantrolene</mesh_term>
	<criteria>Patients must meet follow criterion eligible enrolment : 1 . The patient definitive diagnosis Wolfram syndrome , determine follow : a. Documented functionally relevant recessive mutation allele WFS1 gene dominant mutation one allele WFS1 gene base historical test result ( available ) qualify laboratory screening . 2 . The patient least 5 year age ( biological age ) time write informed consent . 3 . The patient , patient 's parent ( ) , legally authorize guardian ( ) must voluntarily sign Institutional Review Board/Independent Ethics Committeeapproved inform consent form relevant aspect study explain discussed patient . The guardian ' consent patient 's assent , relevant , must obtain . Patients meet follow criterion eligible study : 1 . The patient clinically significant nonWolfram relate CNS involvement judge investigator likely interfere accurate administration interpretation protocol assessment . 2 . The patient know defect oxidative phosphorylation ( confirm mitochondrial myopathy ) 3 . The patient abnormal liver function ( define serum transaminase twice upper limit normal reference laboratory ) 4 . The patient significant medical psychiatric comorbidity might affect study data confound integrity study result . 5 . The patient receive treatment investigational drug within 30 day prior study entry . 6 . The patient receive blood product transfusion within 90 day prior screen . 7 . The patient unable comply protocol , ( e.g . clinically relevant medical condition make implementation protocol difficult , unstable social situation , know clinically significant psychiatric/behavioural instability , unable return safety evaluation , otherwise unlikely complete study ) , determine Investigator . 8 . The patient known history central apnea and/or ventilation requirement . 9 . The patient known history chronic obstructive pulmonary disease , pleural effusion , and/or myocardial disease .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Wolfram syndrome</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Optic Nerve Atrophy</keyword>
	<keyword>Ataxia</keyword>
	<keyword>Endoplasmic Reticulum Stress</keyword>
</DOC>